Amylyx Pharmaceuticals, Inc. AMLX
Set alert
28.04 USD -0.82 -2.84%
At close
28.05 +0.01 +0.04%
Pre-market · Nov 3, 6:11 AM ET
27.61 Day range 29.51
10.83 52-week range 41.14
- YTD
- +132.12%
- 1 year
- +106.18%
- Open
- 28.84
- Prev close
- 28.86
- Mkt cap
- 3.52B
- Vol
- 1.16M
- Avg vol
- 2.19M
- EPS
- -1.41
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 27.61
- High
- 29.51
- Forward P/E
- -25.70
- Beta
- -0.08
- Short ratio
- 9.49
- Inst. own
- 94.36%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 30.89
- 200-d avg
- 20.08
- 1y target
- 42.64
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 42.64 +52.1% upside
Now 28.04
- Target (low)
- 20.00
- Target (mean)
- 42.64
- Target (high)
- 57.00
Ratings (0m) 12 11 buy · 1 hold · 0 sell
- Strong buy0
- Buy11
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 12
- 1 month ago 12
- 2 months ago 12
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.37176 | -0.42 – -0.31407 | -0.37 | -0.5% | 41.60K | 0.0% | 8 |
| Next quarter | -0.36391 | -0.41 – -0.24128 | -0.30 | -21.3% | -41.60K | 0.0% | 8 |
| Current year | -1.48 | -1.60 – -1.26 | -1.53 | +3.0% | 0 | 0.0% | 8 |
| Next year | -1.09 | -1.63 – 0.70 | -1.48 | +26.5% | 28.29M | 0.0% | 8 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | Citigroup | Maintained | Buy | Buy |
| Aug 27, 2026 | Guggenheim | Maintained | Buy | Buy |
| Aug 19, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Aug 19, 2026 | Guggenheim | Maintained | Buy | Buy |
| Aug 19, 2026 | Baird | Maintained | Outperform | Outperform |
| Aug 18, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 17, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Aug 3, 2026 | Citigroup | Maintained | Buy | Buy |
| Jul 20, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Jun 25, 2026 | Guggenheim | Maintained | Buy | Buy |
| Apr 28, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Mar 25, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 19, 2026 | Guggenheim | Maintained | Buy | Buy |
| Mar 4, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 3, 2026 | Stifel | Initiated | — | Buy |
| Feb 20, 2026 | B of A Securities | Maintained | Buy | Buy |
| Feb 10, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 7, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 17, 2025 | Citigroup | Maintained | Buy | Buy |
| Oct 16, 2025 | Baird | Maintained | Outperform | Outperform |
| Oct 3, 2025 | B of A Securities | Maintained | Buy | Buy |
| Sep 16, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Sep 15, 2025 | Guggenheim | Maintained | Buy | Buy |
| Aug 28, 2025 | B of A Securities | Maintained | Buy | Buy |
| Jun 24, 2025 | Guggenheim | Initiated | — | Buy |
| Jun 17, 2025 | Citigroup | Initiated | — | Buy |
| May 14, 2025 | Mizuho | Maintained | Outperform | Outperform |
| May 9, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 7, 2025 | Leerink Partners | Upgrade | Market Perform | Outperform |
| Apr 7, 2025 | Mizuho | Upgrade | Neutral | Outperform |